Truist Securities Maintains Buy on Agilon Health, Lowers Price Target to $23-Report released on 8th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Jailendra Singh has maintained a 'Buy' rating on Agilon Health (NYSE:AGL) but lowered the price target from $27 to $23.

November 09, 2023 | 10:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Agilon Health's price target has been lowered from $27 to $23 by Truist Securities, though the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock, which could counterbalance the negative sentiment to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100